Banking license

Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting

Retrieved on: 
Thursday, June 29, 2023

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.
  • Furthermore, the shareholders granted discharge to the members of the Board of Directors and Executive Management for the financial year 2022.
  • The “Invitation to the 2023 Annual General Meeting” with full proposals and explanations on the agenda items are available on Kinarus’ website at https://ir.kinarus.com/2023-agm/.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting

Retrieved on: 
Thursday, June 29, 2023

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.
  • Furthermore, the shareholders granted discharge to the members of the Board of Directors and Executive Management for the financial year 2022.
  • The “Invitation to the 2023 Annual General Meeting” with full proposals and explanations on the agenda items are available on Kinarus’ website at https://ir.kinarus.com/2023-agm/.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Coherus Prices Public Offering of Common Stock

Retrieved on: 
Tuesday, May 16, 2023

REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share.

Key Points: 
  • REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share.
  • All of the shares of the common stock to be sold in the offering will be offered by Coherus.
  • In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 1,764,705 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • If there are any remaining net proceeds from this offering, Coherus intends to use them for working capital and other general corporate purposes.

Coherus Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, May 15, 2023

REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock.

Key Points: 
  • REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock.
  • In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less the underwriting discount.
  • All of the shares of common stock to be sold in the offering will be offered by Coherus.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

FOMO Pay to Utilize Ripple’s On-Demand Liquidity for Crypto-Enabled Treasury Management

Retrieved on: 
Tuesday, July 26, 2022

In fact, an estimated USD 3.5B is spent annually to address issues associated with treasury and liquidity.

Key Points: 
  • In fact, an estimated USD 3.5B is spent annually to address issues associated with treasury and liquidity.
  • By leveraging ODL for treasury payments, FOMO Pay is able to get 24/7, all year round access to liquidity for EUR and USD, thereby enabling same-day settlement globally.
  • ODL for treasury payments makes it easy for PSPs like FOMO Pay to improve internal business cash flows, thereby allowing them to reduce business costs and improve operations.
  • This is why we are so excited to launch this crypto-enabled treasury management use case for ODL with innovative customers like FOMO Pay.

Quantum-Si Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022

May 09, 2022-- Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), a life sciences company commercializing single molecule protein sequencing, today announced financial results for the first quarter ending March 31, 2022.

Key Points: 
  • May 09, 2022-- Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), a life sciences company commercializing single molecule protein sequencing, today announced financial results for the first quarter ending March 31, 2022.
  • Research and development expenses were $18.8 million in the first quarter of 2022, compared to $8.0 million in the first quarter of 2021.
  • Selling, general and administrative expenses were $8.4 million in the first quarter of 2022, compared to $3.8 million in the first quarter of 2021.
  • Quantum-Si will host a conference call to discuss its first quarter 2022 financial results on Monday, May 9, 2022, at 4:30 PM Eastern Time.

FOMO Pay Forges Strategic Collaboration with Circle to Use USDC for Product Offering

Retrieved on: 
Thursday, March 24, 2022

FOMO Pay will integrate USDC into its services, allowing its merchant, corporate and financial institution clients to seamlessly convert between USDC and fiat currency.

Key Points: 
  • FOMO Pay will integrate USDC into its services, allowing its merchant, corporate and financial institution clients to seamlessly convert between USDC and fiat currency.
  • In November 2021, Circle announced its intention to establish a regional hub in Singapore and participation in a Lighthouse Project with MAS.
  • "FOMO Pay is glad to collaborate with Circle.
  • Neither FOMO Pay nor Circle will service individual customers, or otherwise customers constituting the retail public in Singapore.

Vicarious Surgical Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 8, 2021

Vicarious Surgical Inc. (Vicarious Surgical or the Company) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced third quarter 2021 financial results.

Key Points: 
  • Vicarious Surgical Inc. (Vicarious Surgical or the Company) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced third quarter 2021 financial results.
  • ET on Monday, November 8, 2021 to discuss its third quarter 2021 financial results.
  • Vicarious Surgical believes that the Non-GAAP Financial Measures enhance an investors understanding of Vicarious Surgicals financial performance as it is useful in assessing its operating performance from period-to-period by excluding certain items that Vicarious Surgical believes are not representative of its core business.
  • The Non-GAAP Financial Measures do not replace the presentation of Vicarious Surgicals U.S. GAAP financial results and should only be used as a supplement to, not as a substitute for, Vicarious Surgicals financial results presented in accordance with U.S. GAAP.

Quantum-Si Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, August 16, 2021

Operating expenses were $32.2 million in the second quarter of 2021, compared to $8.2 million in the second quarter of 2020, representing an increase of 292%.

Key Points: 
  • Operating expenses were $32.2 million in the second quarter of 2021, compared to $8.2 million in the second quarter of 2020, representing an increase of 292%.
  • Research and development expenses for the second quarter of 2021 were $13.1 million compared to $6.6 million in the second quarter of 2020.
  • Selling, general and administrative expenses for the second quarter of 2021 were $19.1 million compared to $1.6 million in the second quarter of 2020.
  • A conference call to review the second quarter 2021 financial results is scheduled for August 16, 2021, at 4:30 PM Eastern Time.

FV Bank Selects Fireblocks as Infrastructure Partner for Digital Asset Custody Services

Retrieved on: 
Saturday, June 26, 2021

FV Bank will be leveraging Fireblocks unique MPC-based wallet and network infrastructure to support the introduction of its digital asset custody services which will seamlessly be integrated within FV Banks online banking for its international customers.

Key Points: 
  • FV Bank will be leveraging Fireblocks unique MPC-based wallet and network infrastructure to support the introduction of its digital asset custody services which will seamlessly be integrated within FV Banks online banking for its international customers.
  • FV Bank is the one of the few banks which has a banking license and digital asset custody licenses which will enable FV Bank to offer new services inside a vertically integrated and regulated bank service offering.
  • FV Bank International Inc. (FV Bank) is licensed by the Office of the Commissioner of Financial Institutions (OCIF) with license number IFE-063.
  • FV Bank is redefining international digital banking by seamlessly integrating traditional banking services with digital asset management.